Key Metrics
11.56
Heat Index-
Impact LevelMedium
-
Scope LevelGlobal
-
Last Update2025-09-17
Key Impacts
Positive Impacts (6)
Negative Impacts (6)
Event Overview
The trials highlight the effectiveness of orforglipron in improving HbA1c levels and facilitating weight loss, outperforming existing treatments. This suggests potential advancements in managing type 2 diabetes and obesity, with implications for regulatory approval and market expansion.
Collect Records
Eli Lilly's Orforglipron Shows Superior Efficacy in Type 2 Diabetes Trial
Eli Lilly announced positive top-line results from the ACHIEVE-3 study, a 52-week, open-label, randomized Phase 3 clinical trial. The study evaluated the safety and efficacy of orforglipron compared to oral semaglutide in 1,698 adults with type 2 diabetes who had inadequate blood sugar control with metformin. At 52 weeks, all doses of orforglipron (12mg and 36mg) met the primary and key secondary endpoints, showing superior improvements in HbA1c and weight loss compared to oral semaglutide (7mg and 14mg).
Eli Lilly's Oral Weight Loss Drug Orforglipron Meets Late-Stage Trial Goals
Eli Lilly announced on Tuesday that its once-daily oral weight loss pill, orforglipron, helped obese and type 2 diabetes patients lose weight in a late-stage clinical trial, achieving the study's main goal and paving the way for global regulatory approval. During the 72-week trial, patients taking the highest dose of orforglipron lost an average of 10.5% of their body weight (about 10.4 kilograms), compared to a 2.2% weight loss for those taking a placebo. When including all patients, even those who dropped out, the drug's weight loss effect was 9.6%. Eli Lilly's oral treatment does not have dietary restrictions, unlike similar therapies from competitors.